Another pipeline setback for AstraZeneca

Share this article:
AstraZeneca unveiled a delay in the development of the sepsis treatment Cytofab, less than a year after purchasing the drug to boost its product pipeline. AstraZeneca will conduct further intermediate Phase II clinical trials for Cytofab, which it licensed from the British biotech firm Protherics in a $372 million deal last December. The move could delay the progress of CytoFab by 21 months AstraZeneca spokesman Steve Brown told Reuters. “But that 21 months might come down if we can shorten the timelines in Phase III, given what we do in the additional Phase II program,” Brown said. AstraZeneca had originally planned to start Phase III trials in 2007 and file the drug with regulators sometime after 2008. The announcement comes a week after AstraZeneca scrapped its developmental stroke drug NXY-059, which showed no effect versus placebo in a large clinical trial. Earlier this year, AstraZeneca halted development of two other pipeline hopefuls–the blood-thinner Exanta, which failed to win FDA approval in 2004 because of liver concerns and Type II diabetes drug Galida, following cancer and heart failure concerns.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...